Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine

Journal of Infectious Diseases

Volumn 199, Issue 2, 2009, Pages 184-187

  Lin, Jiang Tao ^a   Li, Chang Gui ^b   Wang, Xu ^c   Su, Nan ^a   Liu, Yan ^c   Qiu, Yuan Zheng ^c   Yang, Meng ^a   Chen, Jiang Ting ^c   Fang, Han Hua ^b   Dong, Xiao Ping ^d   Yin, Wei Dong ^c,f   Feng, Zi Jian ^e,f  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^c Sinovac Biotech Co Ltd   (China)

^d NATIONAL INSTITUTE FOR VIRAL DISEASE CONTROL AND PREVENTION   (China)

^e CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f NONE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNE RESPONSE; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT DURATION; VIRION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINES, INACTIVATED; VIRION; YOUNG ADULT;

EID: 58149344414     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/595832     Document Type: Article

References (15)

1. Claas EC, Osterhaus AD, van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351:472-77.
2. World Health Organization (WHO). H5N1 avian influenza: timeline of major events. Geneva: WHO, 2008. Available at: http://www.who.int/csr/disease/ avian-influenza/Timeline-08%2004-09.pdf. Accessed 22 April 2008.
3. World Health Organization (WHO). Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Geneva: WHO, 2008. Available at: http://www.who.int/csr/disease/avian-influenza/country/cases- table-2008-04-17/en/index.html. Accessed 22 April 2008.
4. Treanor JJ, Wilkinson BE, Masseoud F, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7.
5. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
6. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367:1657-64.
7. Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368:991-7.
8. Leroux-Roels I, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9.
9. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008; 197:580-3.
10. European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). London: European Agency for the Evaluation of Medicinal Products, 2004. Available at: http://www.emea.europa.eu/pdfs/human/vwp/471703en.pdf. Accessed 28 April 2008.
11. Division of Microbiology and Infectious Diseases. Adult toxicity table. Bethesda, Maryland: National Institute of Allergy and Infectious Diseases, 2007. Available at: http://www3.niaid.nih.gov/NR/rdonlyres/401FA10C-8DF2- 4162-8B21-2554129F4294/0/dmidadulttox.doc. Accessed 28 April 2008.
12. Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 2002; 191:203-8.
13. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Sanger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004; 103:163-71.
14. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
15. Stephenson I, Nicholson KG, Colegate A, et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687-93.